Cytosorbents Crp Stock Price To Book

CTSO Stock

USD 0.89 0.01 1.14%

Cytosorbents Crp fundamentals help investors to digest information that contributes to Cytosorbents Crp's financial success or failures. It also enables traders to predict the movement of Cytosorbents Stock. The fundamental analysis module provides a way to measure Cytosorbents Crp's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Cytosorbents Crp stock.

Short Long Term Debt Total Total Assets

As of the 13th of December 2024, Price To Book Ratio is likely to grow to 2.24.

This module does not cover all equities due to inconsistencies in global equity categorizations. Continue to Equity Screeners to view more equity screening tools.

Cytosorbents Crp Company Price To Book Analysis

Cytosorbents Crp's Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities.

P/B

MV Per Share

BV Per Share

More About Price To Book | All Equity Analysis

Current Cytosorbents Crp Price To Book

3.70 X

Most of Cytosorbents Crp's fundamental indicators, such as Price To Book, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Cytosorbents Crp is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.

Cytosorbents Price To Book Driver Correlations

Understanding the fundamental principles of building solid financial models for Cytosorbents Crp is extremely important. It helps to project a fair market value of Cytosorbents Stock properly, considering its historical fundamentals such as Price To Book. Since Cytosorbents Crp's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Cytosorbents Crp's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Cytosorbents Crp's interrelated accounts and indicators.

	Total Assets	Net Debt	Retained Earnings	Total Liab	Total Current Assets	Total Stockholder Equity	Common Stock	Accounts Payable	Good Will	Intangible Assets	Property Plant Equipment	Long Term Debt	Net Receivables	Short Term Debt	Net Tangible Assets	Current Deferred Revenue	Capital Surpluse	Short Long Term Debt	Long Term Debt Total	Long Term Investments	Net Invested Capital	Net Working Capital	Capital Stock
Total Assets		-0.68	-0.78	0.62	0.92	0.93	-0.35	0.69	0.89	0.94	0.77	0.39	0.86	0.04	0.95	0.63	0.9	0.63	0.85	0.76	0.91	0.77	0.79
Net Debt	-0.68		0.17	0.05	-0.89	-0.86	0.17	-0.07	-0.33	-0.43	-0.15	-0.15	-0.29	0.31	-0.81	-0.28	-0.42	-0.31	-0.39	-0.2	-0.87	-0.98	-0.25
Retained Earnings	-0.78	0.17		-0.84	-0.56	-0.55	0.28	-0.82	-0.92	-0.89	-0.78	-0.42	-0.92	-0.37	-0.61	-0.56	-0.89	-0.59	-0.81	-0.86	-0.51	-0.26	-0.81
Total Liab	0.62	0.05	-0.84		0.36	0.29	-0.01	0.81	0.81	0.78	0.8	0.44	0.81	0.45	0.42	0.5	0.7	0.5	0.73	0.78	0.34	0.08	0.71
Total Current Assets	0.92	-0.89	-0.56	0.36		0.97	-0.33	0.44	0.7	0.79	0.51	0.41	0.67	-0.11	0.94	0.49	0.77	0.56	0.75	0.58	0.93	0.93	0.56
Total Stockholder Equity	0.93	-0.86	-0.55	0.29	0.97		-0.41	0.43	0.7	0.78	0.56	0.29	0.65	-0.19	0.96	0.54	0.79	0.55	0.72	0.56	0.93	0.91	0.62
Common Stock	-0.35	0.17	0.28	-0.01	-0.33	-0.41		-0.32	-0.4	-0.42	-0.24	-0.45	-0.41	-0.05	-0.26	-0.21	-0.45	-0.31	-0.34	-0.36	-0.21	-0.17	-0.2
Accounts Payable	0.69	-0.07	-0.82	0.81	0.44	0.43	-0.32		0.89	0.81	0.82	0.4	0.87	0.51	0.53	0.5	0.76	0.52	0.73	0.9	0.45	0.15	0.83
Good Will	0.89	-0.33	-0.92	0.81	0.7	0.7	-0.4	0.89		0.98	0.82	0.54	0.99	0.3	0.74	0.57	0.93	0.63	0.91	0.93	0.67	0.43	0.85
Intangible Assets	0.94	-0.43	-0.89	0.78	0.79	0.78	-0.42	0.81	0.98		0.81	0.59	0.97	0.19	0.79	0.6	0.94	0.64	0.93	0.88	0.73	0.54	0.79
Property Plant Equipment	0.77	-0.15	-0.78	0.8	0.51	0.56	-0.24	0.82	0.82	0.81		0.22	0.77	0.18	0.63	0.68	0.79	0.5	0.72	0.73	0.55	0.29	0.82
Long Term Debt	0.39	-0.15	-0.42	0.44	0.41	0.29	-0.45	0.4	0.54	0.59	0.22		0.58	0.24	0.17	0.1	0.41	0.33	0.6	0.54	0.17	0.18	0.07
Net Receivables	0.86	-0.29	-0.92	0.81	0.67	0.65	-0.41	0.87	0.99	0.97	0.77	0.58		0.3	0.69	0.52	0.91	0.6	0.91	0.93	0.62	0.38	0.82
Short Term Debt	0.04	0.31	-0.37	0.45	-0.11	-0.19	-0.05	0.51	0.3	0.19	0.18	0.24	0.3		-0.1	-0.15	0.16	0.57	0.14	0.48	-0.18	-0.35	0.23
Net Tangible Assets	0.95	-0.81	-0.61	0.42	0.94	0.96	-0.26	0.53	0.74	0.79	0.63	0.17	0.69	-0.1		0.59	0.83	0.57	0.75	0.63	0.95	0.87	0.76
Current Deferred Revenue	0.63	-0.28	-0.56	0.5	0.49	0.54	-0.21	0.5	0.57	0.6	0.68	0.1	0.52	-0.15	0.59		0.64	0.32	0.51	0.38	0.55	0.41	0.63
Capital Surpluse	0.9	-0.42	-0.89	0.7	0.77	0.79	-0.45	0.76	0.93	0.94	0.79	0.41	0.91	0.16	0.83	0.64		0.68	0.93	0.87	0.68	0.52	0.88
Short Long Term Debt	0.63	-0.31	-0.59	0.5	0.56	0.55	-0.31	0.52	0.63	0.64	0.5	0.33	0.6	0.57	0.57	0.32	0.68		0.61	0.69	0.43	0.33	0.58
Long Term Debt Total	0.85	-0.39	-0.81	0.73	0.75	0.72	-0.34	0.73	0.91	0.93	0.72	0.6	0.91	0.14	0.75	0.51	0.93	0.61		0.87	0.62	0.5	0.78
Long Term Investments	0.76	-0.2	-0.86	0.78	0.58	0.56	-0.36	0.9	0.93	0.88	0.73	0.54	0.93	0.48	0.63	0.38	0.87	0.69	0.87		0.48	0.27	0.81
Net Invested Capital	0.91	-0.87	-0.51	0.34	0.93	0.93	-0.21	0.45	0.67	0.73	0.55	0.17	0.62	-0.18	0.95	0.55	0.68	0.43	0.62	0.48		0.92	0.61
Net Working Capital	0.77	-0.98	-0.26	0.08	0.93	0.91	-0.17	0.15	0.43	0.54	0.29	0.18	0.38	-0.35	0.87	0.41	0.52	0.33	0.5	0.27	0.92		0.36
Capital Stock	0.79	-0.25	-0.81	0.71	0.56	0.62	-0.2	0.83	0.85	0.79	0.82	0.07	0.82	0.23	0.76	0.63	0.88	0.58	0.78	0.81	0.61	0.36

Click cells to compare fundamentals

Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.

Competition

Predict Cytosorbents Crp

Price Book Value Ratio Over Time

Cytosorbents Book Value Per Share

Book Value Per Share

0.58

At this time, Cytosorbents Crp's Book Value Per Share is very stable compared to the past year.

Based on the latest financial disclosure, Cytosorbents Crp has a Price To Book of 3.7046 times. This is 85.57% lower than that of the Health Care Equipment & Supplies sector and 34.66% lower than that of the Health Care industry. The price to book for all United States stocks is 61.05% higher than that of the company.

Cytosorbents Price To Book Peer Comparison

Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Cytosorbents Crp's direct or indirect competition against its Price To Book to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Cytosorbents Crp could also be used in its relative valuation, which is a method of valuing Cytosorbents Crp by comparing valuation metrics of similar companies.

Cytosorbents Crp is currently under evaluation in price to book category among its peers.

Cytosorbents Crp Current Valuation Drivers

We derive many important indicators used in calculating different scores of Cytosorbents Crp from analyzing Cytosorbents Crp's financial statements. These drivers represent accounts that assess Cytosorbents Crp's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Cytosorbents Crp's important valuation drivers and their relationship over time.

	2019	2020	2021	2022	2023	2024 (projected)
Market Cap	124.2M	309.4M	181.7M	67.5M	49.6M	47.1M
Enterprise Value	128.1M	239.0M	143.4M	63.6M	53.8M	93.7M

Cytosorbents Fundamentals

	Return On Equity	-1.18
	Return On Asset	-0.28
	Profit Margin	(0.49) %
	Operating Margin	(0.46) %
	Current Valuation	69.28 M
	Shares Outstanding	54.68 M
	Shares Owned By Insiders	3.81 %
	Shares Owned By Institutions	33.28 %
	Number Of Shares Shorted	1.37 M
	Price To Earning	(16.30) X
	Price To Book	3.70 X
	Price To Sales	1.29 X
	Revenue	36.35 M
	Gross Profit	20.73 M
	EBITDA	(28.81 M)
	Net Income	(28.51 M)
	Cash And Equivalents	30.16 M
	Cash Per Share	0.69 X
	Total Debt	18.31 M
	Debt To Equity	0.28 %
	Current Ratio	3.95 X
	Book Value Per Share	0.24 X
	Cash Flow From Operations	(21.66 M)
	Short Ratio	9.57 X
	Earnings Per Share	(0.36) X
	Target Price	5.0
	Number Of Employees	186
	Beta	0.56
	Market Capitalization	48.72 M
	Total Asset	53.26 M
	Retained Earnings	(282.51 M)
	Working Capital	11.16 M
	Current Asset	9.05 M
	Current Liabilities	5 M
	Net Asset	53.26 M

About Cytosorbents Crp Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Cytosorbents Crp's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Cytosorbents Crp using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Cytosorbents Crp based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.

Please read more on our fundamental analysis page.

Pair Trading with Cytosorbents Crp

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cytosorbents Crp position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cytosorbents Crp will appreciate offsetting losses from the drop in the long position's value.

Moving together with Cytosorbents Stock

0.68

Cigna Corp

Pair Corr

Moving against Cytosorbents Stock

0.82	MD	Mednax Inc	Pair Corr
0.81	ECOR	Electrocore LLC	Pair Corr
0.72	VREX	Varex Imaging Corp	Pair Corr
0.59	LH	Laboratory	Pair Corr
0.58	DXCM	DexCom Inc	Pair Corr

The ability to find closely correlated positions to Cytosorbents Crp could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cytosorbents Crp when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cytosorbents Crp - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cytosorbents Crp to buy it.

The correlation of Cytosorbents Crp is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cytosorbents Crp moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cytosorbents Crp moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.

Correlation analysis and pair trading evaluation for Cytosorbents Crp can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.

Pair Correlation Correlation Matching

When determining whether Cytosorbents Crp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Cytosorbents Crp's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Cytosorbents Crp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Cytosorbents Crp Stock:

How To Invest In Cytosorbents

Details

Is Cytosorbents Stock a good investment?

Details

What is Cytosorbents Crp's Net Worth?

Details

Largest Health Care Equipment & Supplies Companies

View

Largest Health Care Equipment & Services Companies

View

Check out Cytosorbents Crp Piotroski F Score and Cytosorbents Crp Altman Z Score analysis.

To learn how to invest in Cytosorbents Stock, please use our How to Invest in Cytosorbents Crp guide.

You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..

Is Health Care Equipment & Supplies space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cytosorbents Crp. If investors know Cytosorbents will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cytosorbents Crp listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.36)

Revenue Per Share

0.72

Quarterly Revenue Growth

0.066

Return On Assets

(0.28)

Return On Equity

(1.19)

The market value of Cytosorbents Crp is measured differently than its book value, which is the value of Cytosorbents that is recorded on the company's balance sheet. Investors also form their own opinion of Cytosorbents Crp's value that differs from its market value or its book value, called intrinsic value, which is Cytosorbents Crp's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cytosorbents Crp's market value can be influenced by many factors that don't directly affect Cytosorbents Crp's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Cytosorbents Crp's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cytosorbents Crp is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cytosorbents Crp's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Cytosorbents Crp Stock Price To Book

Cytosorbents Crp Company Price To Book Analysis

P/B

MV Per Share

BV Per Share

Current Cytosorbents Crp Price To Book

Cytosorbents Price To Book Driver Correlations

Cytosorbents Book Value Per Share

Book Value Per Share

0.58

Cytosorbents Price To Book Peer Comparison

Cytosorbents Crp Current Valuation Drivers

Cytosorbents Fundamentals

About Cytosorbents Crp Fundamental Analysis

Pair Trading with Cytosorbents Crp

Moving together with Cytosorbents Stock

Moving against Cytosorbents Stock

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY